Article
Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
Clinical pharmacology and therapeutics - 1 Jan 2014
Jang S, Atkins M B
Abstract excerpt
The discovery of activating BRAF mutations in melanomas has led to the investigation of small molecular inhibitors targeting BRAF mutation and MEK, a downstream protein within the mitogen-activated protein kinase (MAPK) pathway. This article reviews the role of mutant BRAF in melanoma and summarizes the results of clinical trials evaluating inhibitors of BRAF and MEK in BRAF-mutant melanoma. We further describe...
Topics
Join the communities discussing this publication.